1. Moscow’s Clinical Research Practical Center (Moscow, Russian Federation)

Keywords:ulcerative colitis,prevalence,pathogenesis,immune status,nutritional support

Abstract:The article describes the modern data on the prevalence of ulcerative colitis, presents data on the factors of pathogenesis, main tasks, directions and scheme of nutritional support depending on the activity of the disease, nutritional deficiency and immune status of the patient.

• References total 34 ⇓ :: .
  1. Magro F, Langner C, Driessen A, Ensari A, Geboes K. et al. Europ Soc Pathol; Europ Crohn’s Colitis Org(ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013 Nov;7(10):827-51. doi: 10.1016/j.crohns.2013.06.001
  2. Неспецифические воспалительные заболевания кишечника / Под ред. Г. И. Воробьева, И. Л. Халифа. - М.: Миклош, 2008. - 399 с.
  3. Ивашкин В.Т., Маев И. В., Лапина Т. Л., Шептулин А. А. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению взрослых больных язвенным колитом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;1:48-89. 2015;1:48-89
  4. Sarlos P, Kovesdi E, Magyari L, Banfai Z, Szabo A, Javorhazy A, Melegh B. Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):304-21. doi: 10.4291/wjgp.v5.i3.304.
  5. Коненков В.И., Смольникова М. В. Структурные основы и функциональная значимость аллельного полиморфизма генов цитокинов человека и их рецепторов // Мед иммунол. 2003; 5(1-2):11-28. 2003; 5(1-2):11-28.
  6. Самоходская Л.М., Игнатова Т. М., Абдуллаев С. М., Краснова Т. Н., Некрасова Т. П., Мухин Н. А., Ткачук В. А. Прогностическое значение комбинации аллельных вариантов генов цитокинов и гемохроматоза у больных хроническим гепатитом С // РЖГГК.2007;2:50-56. PubMed PMID: 17338374.
  7. Roussomoustakaki М. et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997; 112 (6):1845-1853. PubMed PMID:9178675.
  8. Основанный на доказательствах Европейский консенсус по диагностике и лечению язвенного колита / Нац. Группа по воспалительным заболеваниям кишечника Респ. Беларусь; ред- кол.: Ю. Х. Мараховский [и др.]. Минск, 2008. - 216 с.
  9. Макейкина М.А., Ливзан М. А. Генетические прогностические факторы течения неспецифического язвенного колита. Практич медиц. 2012; 9 (65):133-136. PubMed PMID: 24933943.
  10. Farrell R.J., Peppercorn M. A. Ulcerative colitis. The Lancet. 2002;359:331-40. DOI:10.1016/S 0140-6736(02)07499-8
  11. Сатырова Т. В., Михайлова Е. И. Язвенный колит: современный взгляд на этиологию и патогенез (обзор литературы). Проблемы здоровья и экологии. 2010; (2 (24):7-11. 2010; (2 (24):7-11.
  12. Омаров Т.Р., Омарова Л. А. Неспецифический язвенный колит и влияние кандидоза на иммунный статус. Клин мед Казахстана. 2014;4(34):54-57. 2014;4(34):54-57.
  13. Никитин В.Ю., Сухина И. А., Цыган В. Н. и др. Маркеры активации на Т-хелперах и цитотоксических лимфоцитах на различных стадиях хронического вирусного гепатита С. Вестник РАМН. 2007; 17(1):65-71. 2007; 17(1):65-71.
  14. Лебедева Т. Н. Иммунитет при кандидозе. Пробл мед микол. 2004; 6(4):8-16. 2004; 6(4):8-16.
  15. Бурова С. А. Современные представления о грибковой патологии пищеварительного тракта. Леч врач. 2005;6:52-66. 2005;6:52-66.
  16. Шептулин А. А. Как изменились подходы к лекарственной терапии язвенного колита за последние 30 лет. Клин Мед 2015;93(8):50-4. PubMed PMID: 26669032.
  17. Friedman S. Inflammatory Bowel Disease. In: Harrison’s Internal Medicine / S. Friedman // McGraw-Hill Access Medicine. - 2006. - The McGraw-Hill Companies. Available at: www.accessmedicine.com/ content.aspx?aID=90323.
  18. Михайлова Е. И. Актуальные вопросы этиологии, патогенеза и диагностики воспалительных и онкологических заболеваний кишечника: монография / Е. И. Михайлова. - Гомель, ГГМУ, 2009. - 182 с.
  19. Balding J, Livingstone WJ, Conroy J., et al. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm. 2004 Jun;13(3):181-7. PubMed PMID: 15223609; PubMed Central PMCID: PMC 1781555.
  20. van Assche G., Rutgeerts P. Antiandhesion molecule therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 2002; 8: 291-300. PubMed PMID: 12131614.
  21. Mac Donald T. T., Monteleone G. Adaptive immunity: Effector and inhibitory cytokine pathways in gut inflammation. In: S. R. Targan, F. Shanahan, L. C. Karp (eds.). Inflammatory bowel disease. Translating basic science into clinical practice. Chichester: Wiley Blackwell. 2010. P. 82-91. 2010. P. 82-91.
  22. Баранов А. А., Потапов А. С., Цимбалова Е. Г. Современные технологии диагностики и лечения воспалительных заболеваний кишечника у детей. Вестн. РАМН. 2011; 6: 36-41. PubMed PMID: 21786603.
  23. Salmi M, Granfors K, MacDermott R, Jalkanen S. Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases. Gastroenterology. 1994;106:596-605. PubMed PMID: 8119529.
  24. Nakamura S, Ohtani H, Watanabe Y, Fukushima K, Matsumoto T, Kitano A, Kobayashi K, Nagura H. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest. 1993;69:77-85. PubMed PMID: 7687311.
  25. Khazen D, Jendoubi-Ayed S, Aleya WB. et al. Polymorphism in ICAM-1, PECAM-1, E-selectin, and L-selectin genes in Tunisian patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:167-175. doi: 10.1097/MEG.0b013e32830e6fc8.
  26. Ашкинази В.И., Маянская И. В., Толкачёва Н. И. и др. Молекулы адгезии при деструктивно- воспалительном процессе в кишечнике у детей с язвенным колитом. Вопр совр педиатр. 2013;12(4):52-56. 2013;12(4):52-56.
  27. von Andrian U. H., & Mackay C. R. T-cell function and migration - two sides of the same coin. New England J Med 2000; 343(14):1020-1034. DOI:10.1056/NEJM200010053431407
  28. Abbas et al. Basic Immunology. Functions and Disorders of the Immune System (4th Ed) Elsevier, Philadelphia, 2012.
  29. Халиф И.Л., Шапина М. В. Эффективность ведолизумаба при воспалительных заболеваниях кишечника. Рос журн гастроэнтерол гепатол колопроктол 2016; 26(6):92-100. 2016; 26(6):92-100.
  30. Щербаков И. Г. Патоморфология слизистой оболочки желудочно-кишечного тракта при острых бактериальных, вирусно-кишечных инфекциях и хронических колитах. Автореф… дис докт мед наук. Москва, 1996.
  31. Шифрин О. С. Современные подходы к лечению больных неспецифическим язвенным колитом. Consil med. 2002; 24-29. 2002; 24-29.
  32. Костюченко Л. Н. Нутрициология в гастроэнтерлогии: рук. Для врачей. М.:, ООО «МК», 2013. - 432 с
  33. Лычкова А.Э., Пузиков А. М. Моторика желудочно-кишечного тракта при постгастрорезекционном синдроме Экспер клин гастроэнтерол. 2015; (8): 25-29. PubMed PMID: 27017739.
  34. Лычкова А. Э. Координация миоэлектрической активности тонкой и толстой кишки. Экспер клин гастроэнтерол. 2012;3:59-61. PMID:22830225

Full text is published :
Smirnova O.A., Lychkova A.E., Kostyuchenko L.N., Puzikov A.M. ULCERATIVE COLITIS: A MODERN VIEW ON SOME PROBLEMS . Experimental and Clinical Gastroenterology Journal. 2017;141(05):04-13
Read & Download full text

1. Gamaleya Federal Research Centre for Microbiology and Immunology of the Ministry of Public Health (Moscow, Russian Federation)
2. Botkin Hospital of Moscow Department of Public Health; Sechenov the First Moscow Medical University of the Ministry of Public Health (Moscow, Russian Federation)

Keywords:Helicobacter pylori,biofilm,scanning electron microscopy

Abstract:Using scanning electron microscopy, the ability of reference and freshly isolated Helicobacter pylori strains to form biofilm under cultivation on abiotic surfaces and in natural conditions was studied. It was shown that both types of strains were capable of biofilm formation in vitro, although reference strains synthesized less pronounced exocellular matrix and flagella than freshly isolated strains. Bio-film also was detected in specimens of antral mucosa under duodenal ulcer. Most often Helicobacter pylori biofilms were detected near the mouths of the gastric glands. The structure of matrix surface of such biofilms looked inhomogeneous in different parts of the epithelial layer.

• References total 15 ⇓ :: .
  1. Eusebi L.H., Zagari R. M., Bazzoli F. Epidemiology of Helicobacter pylori infection // Helicobacter. - 2014. - v. 19 (Suppl. 1). - P. 1-5.
  2. Amieva M. R., El-Omar E. M. Host-bacterial interactions in Helicobacter pylori infection // Gastroenterology. - 2008. - v. 134. - P. 306-323.
  3. Wroblewski L.E., Peek R. M., Wilson K. T. Helicobacter pylori and gastric cancer: factors that modulate disease risk // Clin. Microbiol. Rev. - 2010. - v. 23. - P. 713-739.
  4. Shiota S., Suzuki R., Yamaoka Y. The significance of virulence factors in Helicobacter pylori // J. Dig. Dis. - 2013. - v. 14. - No. 7. - P. 341-349.
  5. Sgouras D.N., Trang T. T.H., Yamaoka Y. Pathogenesis of Helicobacter pylori infection // Helicobacter. - 2015. - v. 20. No. 1. - P. 8-16.
  6. Salama N.R., Hartung M. L., Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori // Nat. Rev. Microbiol. - 2013. - v. 11. - No 6. - P. 385-399.
  7. Rhee K.H., Park J. S., Cho M. J. Helicobacter pylori: bacterial strategy for incipient stage and persistent colonization in human gastric niches // Yonsei Med. J. - 2014. - v. 55. - No. 6. - P. 1453-1466.
  8. Cellini L. A chameleon-like approach to life // World J. Gastroenterol. - 2014. - 20 (19). - P. 5575-5582.
  9. Costerton J. W. Lewandowski Z., Caldwell D. E. et al. Microbial biofilms // Annu. Rev. Microbiol. - 1995. - v. 41. - P. 435-464.
  10. Costerton J. W., Cheng K.-J., Geesey G. G. et al. Bacterial biofilms in nature and disease // Annu. Rev. Microbiol. - 1987. - v. 49. - P. 711-745.
  11. Cole S., Harwood J., Lee R., She R., Guineyr D. G. Chracterization of monospecies biofilm formation by Helicobacter pylori // J. Bacteriol. - 2004. - v. 10. - P. 3124-3132.
  12. Carron M. A., Tran V. R., Sugawa C., Coticchia J. M. Identification of Helicobacter pylori biofilms in human gastric mucosa // J. Gastrointest. Surg. - 2006. - v. 10. - No. 5. - P. 712-717.
  13. Andersen L. P., Rasmussen L. Helicobacter pylori-coccoid forms and biofilm formation // FEMS Immunol. Med. Microbiol. - 2009. - v. 56. - No. 2. - P. 112-115.
  14. Zhukhovitsky V. G. Coccoid forms of Helicobacter pylori to be cut off with Occam’s razor! // Intern. J. Med. Microbiol. - 2001. - v. 291 (Suppl. 31). - abst. # K/19. - P. 99.
  15. Жуховицкий В. Г. Микробиологическая диагностика хеликобактериоза // Эксперимент. клин. гастроэнтерол. - 2008. - № 8. - С. 34-45.

Full text is published :
Zhukhovitsky V.G., Smirnova T.A., Shevlyagina N.V., Korzheva I.Yu. et al. HELICOBACTER PYLORI BIOFILM IN VITRO AND IN VIVO. Experimental and Clinical Gastroenterology Journal. 2017;141(05):14-19
Read & Download full text

1. Outpatient clinic N 3 of the Presidential Administration of the Russian Federation (Moscow, Russian Federation)
2. Moscow clinical scientific center (Moscow, Russian Federation)

Keywords:pregnancy,Helicobacter pylori,early toxicosis,vomiting of pregnancy,anemia

Abstract:Aim of the study. To investigate the effect of Helicobacter pylori infection on pregnancy and its outcome. Material and methods. An observational study involving 200 pregnant women divided into 3 groups. The first group included 100 women suffering from diseases associated with H. pylori, in the second - 50 pregnant women with digestive diseases, but H. pylori negative, a third - 50 healthy women. Results. It has been shown that women infected with H. pylori, significantly more likely to have the non-developing pregnancy in history, higher duration and severity of early toxicity, the frequency and severity of anemia in pregnant women, as well as the incidence of vaginal candidiasis. However, the presence of H. pylori had no effect on outcome of pregnancy, fetal development and weight and neonatal growth indicators.

• References total 18 ⇓ :: .
  1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht V/ Florence Consensus Report // Gut. 2016 Oct 5. pii: gutjnl-2016-312288. doi: 10.1136/gutjnl-2016-312288. [Epub ahead of print]
  2. Бордин Д. С., Бяхов М. Ю., Федуленкова Л. В. «Серологическая биопсия» и скрининг рака желудка //Злокачественные опухоли 2014;2(9):30-36.
  3. Бурков С. Г., Бурдина Е. Г. Эрадикация инфекции хеликобактер пилори - краеугольный камень терапии язвенной болезни // Consilium Provisorum. 2005;2:27-29.
  4. Karaer A., Ozkan O., Ozer S. Gastrointestinal symptoms and Helicobacter pylori infection in early pregnancy. A seroepidemiologic study // Gynecol. Obstet. Invest. 2008; 66:44-46.
  5. Sandven I., Abdelnoor M., Wethe M. Helicobacter pylori infection and hyperemesis gravidarum. An institution-based case-control study // Eur. J. Epidemiol. 2008;23:491-498.
  6. Clark SM, Dutta E, Hankins GD. The outpatient management and special considerations of nausea and vomiting in pregnancy // Semin Perinatol. 2014;38(8):496-502.
  7. Kazemzadeh M, Kashanian M, Baha B, Sheikhansari N. Evaluation of the relationship between Helicobacter Pylori infection and Hyperemesis Gravidarum // Med J Islam Repub Iran. 2014;28:72.
  8. Boltin D, Perets TT, Elheiga SA, Sharony A, Niv Y, Shamaly H, Dickman R. Helicobacter pylori infection amongst Arab Israeli women with hyperemesis gravidarum - a prospective, controlled study // Int J Infect Dis. 2014;29:292-295.
  9. Poveda GF, Carrillo KS, Monje ME, Cruz CA, Cancino AG. Helicobacter pylori infection and gastrointestinal symptoms on Chilean pregnant women // Rev Assoc Med Bras. 2014;60(4):306-310.
  10. Niemeijer MN, Grooten IJ, Vos N, Bais JM, van der Post JA, Mol BW, Roseboom TJ, Leeflang MM, Painter RC. Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis // Am J Obstet Gynecol. 2014;211(2):150.e1-15.
  11. Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders // World J Gastroenterol. 2014;20(3):654-664.
  12. Duley L. The global impact of pre-eclampsia and eclampsia // Semin Perinatol 2009; 33:130-137.
  13. Ponzetto A, Cardaropoli S, Piccoli E, Rolfo A, Gennero L, Kanduc D, et al. Pre- eclampsia is associated with Helicobacter pylori seropositivity in Italy // J Hypertens 2006; 24:2445-2449.
  14. Franceschi F, Di Simone N, D’Ippolito S, Castellani R, Di Nicuolo F, Gasbarrini G, et al. Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia? // Helicobacter 2012; 17:426-434.
  15. Tersigni C, Franceschi F, Todros T, Cardaropoli S, Scambia G, Di Simone N. Insights into the Role of Helicobacter pylori Infection in Preeclampsia: From the Bench to the Bedside // Front Immunol. 2014;5:484
  16. Лазебник Л. Б., Васильев Ю. В., Щербаков П. Л., Хомерики С. Г., Машарова А. А., Бордин Д. С., Касьяненко В.И, Дубцова Е. А. Helicobacter pylori: распространенность, диагностика, лечение //Экспериментальная и клиническая гастроэнтерология 2010;2:3-7.
  17. Барышникова Н. В., Ткаченко Е. И., Успенский Ю. П. Современные аспекты состояния проблемы Helicobacter pylori - ассоциированных заболеваний / в книге Гастроэнтерология. Болезни взрослых / под общ. ред. Л. Б. Лазебника, П. Л. Щербакова. - М.: МК, 2011 - С. 103.
  18. Цуканов В. В., Хоменко О. В., Ржавичева О. С., Буторин Н. Н., Штыгашева О. В., Маады А. С., Бичурина Т. Б., Амельчугова О. С. Распространенность Helicobacter pylori и ГЭРБ у монголоидов и европеоидов восточной Сибири // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2009;19(3):38-41.

Full text is published :
Burkov S.G., Bordin D.S., Sharapova E.I., Markina N.F. INFLUENCE OF HELICOBACTER PYLORI ON CLINICAL COURSE OF PREGNANCY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):20-23
Read & Download full text

1. State funded medical institution “City clinical hospital № 15 named after O. M. Filatov” Department of healthcare of Moscow (Moscow, Russian Federation)
2. State funded institution of higher professional education “Moscow State Medical and Dental University of A. I. Evdokimov” (Moscow, Russian Federation)

Keywords:Crohn’s disease,infliximab,infliximab concentration in blood serum,infliximab pharmacokinetics,anticytokine therapy,mesenchymal stromal cells of the bone marrow

Abstract:The therapeutic effect of infliximab (INFL) in Crohn’s disease (CD) patients receiving anticytokine therapy depends on the concentration of the medication in the blood serum. When INFL concentration in the blood serum is high (more than 20 μg/ml) the clinical and endoscopic remission of CD is observed in the patients. Upon the second administration INFL is not accumulated in the organism. After the induction course of INFL the level of the medication in the blood serum increases (more than 45 μg/ml), further its serological concentration gradually decreases approaching the values below the minimum. The transplantation of mesenchymal stromal cells of the bone marrow contributed to the increase of INFL level in the blood serum and to the recovery of sensitivity to INFL.

• References total 13 ⇓ :: .
  1. Насонов Е. Л. Фактор некроза опухоли -α новая мишень для противовоспалительной терапии ревматоидного артрита // РМЖ.-2000.-т.8.-№ 17.-с.718-722.
  2. Насонов Е. Л. Моноклональные антитела к фактору некроза опухоли -α в ревматологии // РМЖ.-2003.-№ 7.-с.718-722.
  3. Сагынбаева В. Э., Лазебник Л. Б., Князев О. В., Ефремов Л. И. Антитела к инфликсимабу и к антигенам HLA-I и II класса как свидетели иммунного ответа на биолгическую терапию воспалительных заболеваниях кишечника // Экспер. и клинич. гастроэнтер. 2011. № 12. -с. -49-53.
  4. Keating G. M., Perry C. M. Infliximab: an updated review of its use in Crohns disease and rheumatoid arthritis, BioDroge.-2002/-16 (2).111-48.
  5. Han P. D., Cohen R. D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohns disease. Gruds.-2004.-64(16): 1767-77.
  6. Remicade approved for children with Crohns disease. FDA Comsun.-2006 Jul-Aug.-40(4).-6.
  7. Халиф И. Л. Биологическая терапия болезнь Крона // Методическая рекомендация. Выпуск 1. -2011. - Стр. 20.
  8. Klotz U., Teml A., Schwab M. Clinical pharmacokinetics and of infliximab // Clin pharmacokinet 2007; 46: 645-60.
  9. Fasanmade AA., Adedokun OJ., Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis // Int J Clin Pharmacol Ther 2010; 48: 297-308.
  10. Fasanmade AA., Adedokun OJ., Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis // Eur J Clin Pharmacol 2009; 65: 1211-28
  11. Pollono EN., Lopez-Olivo MA., Iopez JA, et al. A systematic review of the effect of TNF-alpha antagonist on lipid profiles in patients with rheumatoid arthritis// Clin Rheum Dis 2010; 69: 817-21
  12. Xu Z., Seitz K., Fasanmade A., Ford J., Williamson P., Xu W., Davis H. M., Zhou H. Population pharmacokinetics of infliximab in patients with ankylosind spondylitis, J Clin Pharmacol.-2008. Jun; 48 (6): 681-95. Epub 2008 Apr 9.
  13. Elliott M. J., Maini R. N., Feldmann M., Long -Fox A., Chariles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis, Lancet.-1994.-Oct 22.-344 (8930).-1125-7).

Full text is published :
Sagynbaeva V.E., Lazebnik L.B., Golovanova E.V. THERAPEUTIC CONCENTRATION OF INFLIXIMAB IN THE BLOOD SERUM OF CROHN’S DISEASE PATIENTS RECEIVING ANTICYTOKINE THERAPY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):24-28
Read & Download full text

1. Federal State Budgetary Educational Institution of Higher Education “National Research Ogarev Mordovia State University” (Saransk, Russian Federation)
2. Federal State Health Institution Clinical Hospital 50 Federal Medical - Biological Agency Russian, clinic 1, Women’s Center (Saransk, Russian Federation)

Keywords:drug-induced hepatitis,pregnancy,medicines,biochemical activity of drug-induced hepatitis

Abstract:Purpose of the study. To characterize drug-induced hepatitis in pregnant women. Materials and methods: a clinical examination, a retrospective analysis of the exchange of cards and 67 birth stories of women. Results. Drug-induced hepatitis often diagnosed at 39 weeks of gestation. Overweight and comorbidities biliary system increases the biochemical activity of drug-induced hepatitis. The clinical picture is dominated by asymptomatic version of the flow, but monosemeiotic option complaining of itchy skin, accompanied by higher rates of liver transaminases. Among biochemical syndromes prevailed cytolytic and cholestatic options, and the degree of activity of transaminases usually defined as the minimum and reasonable. Drug-induced hepatitis in pregnant women developed in patients receiving combinations of 5 or more drugs, which included vitamin - mineral complexes, progestogens, folic acid preparations, iodine preparations. The degree of hepatitis activity was in direct proportion to the number of drugs taken.

• References total 3 ⇓ :: .
  1. Еремина Е. Ю., Герасименко И. В. Лекарства и печень. // Алфавит. - 2013. - № 2. - С. 18-22.
  2. Еремина Е. Ю., Герасименко И. В., Герасименко А. В. Лекарственные поражения печени у беременных. // Медицинский альманах. - 2013. - № 1. - С. 55-59.
  3. Ozsvár Z., Solymossi Z., Monostory K. Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver / // Orv Hetil. - 2010. - 151(11):457-61.

Full text is published :
Gerasimenko I.V., Chernova O.V. DRUG-INDUCED HEPATITIS IN PREGNANT WOMEN. Experimental and Clinical Gastroenterology Journal. 2017;141(05):29-32
Read & Download full text

1. FSBIS RCPCM FMBA of Russia (Moscow, Russian Federation)

Keywords:Escherichia coli,Crohn’s disease,experimental animal models,Escherichia coli

Abstract:Crohn’s disease (CD), a member of inflammatory bowel disease group (IBD), is a chronic relapsing disease of unknown origin. It is considered, that the pathogenesis of CD involves aberrant immune reactions in response to the pathogenic intestinal microflora, in particular opportunistic E. coli, but the exact cause of the disease still remains unknown. Therefore, the CD therapy depends on the stage of the disease and remains symptomatic. The most effective method for pathogenesis study of the CD and the selection of appropriate treatment is in vivo CD models. Today, there are more than sixty different animal models of CD, conventionally divided into four groups: chemical induction of the disease, the introduction of specific pathogen into model object, spontaneous occurrence of the disease in genetically modified animals and transplantation of immune system cells into immunodeficient animals.

• References total 29 ⇓ :: .
  1. Каркищенко Н.Н., Грачев С. В. Руководство по лабораторным животным и альтернативным моделям в биомедицинских исследованиях: учебное пособие для системы медицинского и фармацевтического послевузовского образования. - М.: Профиль, 2010. - 358 с.
  2. Сидорчук А.А., Глушков А. А. Инфекционные болезни лабораторных животных. Учебное пособие, 1-е изд. - М.: Лань, 2009. -128 с.
  3. Allan R.N., Rhodes J. M., Hanauer S. B. (eds) Inflammatory bowel diseases, 3rd edn. - London: Churchill Livingstone, 1997. - P. 863.
  4. Barnich N. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease / Barnich N., Carvalho F. A., Glasser A. L. et al. //J Clin Invest. - 2007. - № 6 (117). - P. 1566-1574.
  5. Carvalho F. A. Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. // J Exp Med. - 2009. - № 10 (206). - P. 2179-89.
  6. Corridonia D. Inflammatory bowel disease / Corridonia D., Arseneau K. O., Cominellia F. // Immunology Letters. - 2014. - № 2 (161). - P. 231-235.
  7. Craven M. Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn’s disease / Craven M., Egan C. E., Dowd S. E. et al. // PLoS One. - 2012. - № 7 (7). - e41594. doi: 10.1371/journal.pone.0041594.
  8. Eckburg P. B. Diversity of the human intestinal microbial flora / Eckburg P. B., Bik E. M., Bernstein C. N. et al. // Science. - 2005. - № 308 (5728). - P. 1635-1638.
  9. Gevers D. The treatment-naive microbiome in new-onset Crohn’s disease / Gevers D., Kugathasan S., Denson L. A. et al. // Cell Host Microbe. - 2014. - № 3(15) - P. 382-392.
  10. Golovics P. A. Inflammatory bowel disease course in Crohn’s disease: Is the natural history changing? / Golovics P. A., Mandel M. D., Lovasz B. D. et al. // World J Gastroenterol. - 2014. - № 12 (20). - P. 3198-3207.
  11. Hale L. P. A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features / Hale L. P., Greer P. K. // PLoS ONE. - 2012. -№ 7 (7). - e41797.doi:10.1371/journal.pone.0041797.
  12. Kojima R. Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis / Kojima R., Kuroda S., Ohkishi T. et al. // J Pharmacol Sci. - 2004. - № 3 (96). - P. 307-313.
  13. Laroux F. S. Regulation of chronic colitis in athymic nu/nu (nude) mice / Laroux F. S., Norris H. H., Houghton J. et al. // Int Immunol. - 2004. - № 1 (16). - P. 77-89.
  14. Ley R. E. Obesity alters gut microbial ecology / Ley R. E., Bäckhed F., Turnbaugh P. et al. // Proc Natl Acad Sci U S A. -2005. - № 31(102). - P. 11070-11075.
  15. Liao S. L. Maturation ofToll-like receptor 1-4 responsiveness during early life / Liao S. L., Yeh K. W., Lai S. H. et al. // Early Hum Dev. - 2013. - № 7 (89). - P. 473-478.
  16. Louis E. From evidence-based medicine to personalized medicine in Crohn’s disease / Louis E., Reenaers C., Van Kemseke C. et al. // Rev Med Liege. - 2015. - № 5 (70). - P. 316-320.
  17. Mahler M. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis / Mahler M., Bristol I. J., Leiter E. H. et al. // American Journal of Physiology. -1998. - № 3 (274). - P. 544-551.
  18. Martinez-Medina M. Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity / Martinez-Medina M., Garcia-Gil L.J. // World J Gastrointest Pathophysiol. - 2014. - № 3(5). - P. 213-227.
  19. Mizoguchi A. Animal models of inflammatory bowel disease. Progress in molecular biology and translational science // Prog Mol Biol Transl Sci. - 2012. - № 105. - P. 263-320.
  20. Morampudi V. DNBS/TNBS colitis models: providing insights into inflammatory bowel disease and effects of dietary fat / Morampudi V., Bhinder G., Wu X. et al. // J. Vis. Exp. - 2014. - № 84. - e51297. doi: 10.3791/51297.
  21. Nguyen T. L. A. How informative is the mouse for human gut microbiota research? / Nguyen T. L.A., Vieira-Silva S., Liston A., Raes J. // Dis Model Mech. - 2015. - № 1(8). - P. 1-16.
  22. Pizarro T. T. SAMP1/YitFc mouse strain: a spontaneous model of Crohn’s disease-like ileitis / Pizarro T. T., Pastorelli L., Bamias G. et al. // Inflammatory bowel diseases. - 2011. - № 12 (17). - P. 2566-2584.
  23. Powrie F. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD 45RBhi CD 4+ T cells / Powrie F., Leach M. W., Mauze S. et al. // Immunity. - 1994. - № 1(7). - P. 553-562.
  24. Randhawa P. K. A review on chemical-induced inflammatory bowel disease models in rodents / Randhawa P. K., Singh K., Singh N. // Korean J Physiol. - 2014. - № 4 (18). - P. 279-88.
  25. Reingold L. Development of a peptidoglycan-polysaccharide murine model of Crohn’s disease: effect of genetic background / Reingold L., Rahal K., Schmiedlin-Ren P. et al. // Inflamm Bowel Dis. - 2013. - № 6 (19). - P. 1238-1244.
  26. Remond D. Intestinal inflammation increasesgastrointestinal threonine uptake and mucin synthesis in enterally fed minipigs / Remond D., Buffiere C., Godin J. et al. // J. Nutr. - 2009. -№ 4 (139). - P. 720-726.
  27. Roulis M. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology / Roulis M., Armaka M., Manoloukos M. et al. // PNAS. - 2011. - № 13 (108). - P. 5396-5401.
  28. Treuting P. M. Lower gastrointestinal tract / Treuting P. M., Dintzis S. M. // Comparative anatomy and histology. A mouse and human atlas, 1st edn. - 2012. - P. 177-192.
  29. van Mierlo G. J. D. The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab / van Mierlo G. J.D., Cnubben N. H.P., Wouters D. et al. // J Immunotoxicol. - 2014. - № 1 (11). - P. 62-71.

Full text is published :
Baykova Yu.P., Rakitina D.B., Shcherbakov P.L., Govorun V.M. EXPERIMENTAL ANIMAL MODELS OF CROHN’S DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;141(05):33-38
Read & Download full text

1. Ogarev Mordovia State University (Saransk, Russian Federation)

Keywords:liver,pancreas,free radical oxidation,obstructive cholestasis,ozone

Abstract:Objective: The goals of this investigation is to study experimentally the effectiveness of intravenous infusions of ozonated 0.9 % sodium chloride solution for the correction of free-radical oxidation processes in acute obstructive cholestasis. Materials and methods: In 40 dogs under thiopental sodium (0.045-0.050 g / kg body weight) anesthesia was simulated a mechanical jaundice with the applying a loop on the common bile duct. Animals were divided into 4 series. In the first and second series after the simulation of cholestasis the common bile duct was decompressed on the third day. In the 3rd and 4th series after the decompression of the common bile duct for 4 days it were 0.9 % chloride and ozonized isotonic sodium chloride solution (OIS) infused. The pro- and antioxidant status were measured with the help of the luminescence induced plasma chemiluminescence intensity (Imax, S) in homogenates of the pancreas, the determination of the level of malondialdehyde (MDA) and catalase. Results. When ligation common bile duct the total bilirubin level was 40.3 times higher on the 3rd day of the experiment than in baseline. Imax index was increased by 2.7 times, chemiluminescence light sum - by 2.6 times of the original value. When ozone intravenous infusion for 7 days the maximal chemiluminescence intensity was decreased by 1.7 times and S parameter - by 68 %. Conclusion. Progressive obstructive jaundice in animals was accompanied by an increase in the intensity of free radical processes. But the infusions OIS followed by a significant decrease in the intensity of free radical processes that expressed by the decreasing in the amount of lipid peroxidation and was accompanied by increasing of antioxidant enzymes activity.

• References total 7 ⇓ :: .
  1. Walkowiak J. Normal levels of serum pancreatic enzymes in patients with progressive familial intrahepatic cholestasis type 2 / J. Walkowiak, I. Jankowska, A. Lisowska et al. // Act. Biochim. Pol. - 2010. - Vol.57(4). - Р. 573-575.
  2. Assimakopoulos S. F., Scopa C. D., Vagianos C. T. Pathophysiology of increased intestinal permeability in obstructive jaundice // World J. Gastroenterol. - 2007. - Vol. 13 (48). - Р. 6458-6464.
  3. Starosek V. N., Khil’ko S.S., Vlakhov A. K. et al. Modern tendencies in surgical treatment of patients with obturation jaundice complicated by hepatic insufficiency // Klincheskaya Khirurgiya. - 2009. - Vol. (4). - Р. 15-18.
  4. Орлов Ю. П., Долгих В. Т. Свободнорадикальное окисление и антиоксидантная терапия при критических состояниях // Вестник интенсивной терапии. - 2008. - № 1 - С. 73-77.
  5. Беляев А. Н., Козлов С. А., Беляев С. А., Костин С. В. Функциональные и морфологические нарушения печени при остром обтурационном холестазе и их коррекция (экспериментальное исследование) // Анналы хирургической гепатологии. - 2014. - Т. 19. - № 4. - С. 64-70.
  6. Беляев А. Н., Беляев С. А., Костин С. В. и соавт. Патогенетическая коррекция нарушений гемостаза при остром обтурационном холестазе // Медицинский альманах. - 2010. - № 1. - С. 136-140.
  7. Беляев А. Н., Беляев С. А., Юдин А. А. и соавт. Гепатопротекторная активность озона при остром внепеченочном холестазе // Вестник физиотерапии и курортологии. - 2008. - № 5. - С. 107-109.

Full text is published :
Belyaev A.N., Kostin S.V., Belyaev S.A., Zakhvatov A.N. EFFECTS OF OZONE ON FREE RADICAL OXIDATION IN ACUTE OBSTRUCTIVE CHOLESTASIS. Experimental and Clinical Gastroenterology Journal. 2017;141(05):39-42
Read & Download full text

1. Federal state budgetary educational institution of higher professional education “Saratov state medical University named after V. I. Razumovsky” Ministry of health of the Russian Federation (Saratov, Russian Federation)

Keywords:pregnancy,heartburn,GERD

Abstract:Heartburn is one of the most frequent and resistant symptoms in pregnancy. Although complications are rare, heartburn may reduce the quality of life, and forces to use pharmacotherapy. The lecture describes the main approaches to the diagnostic, non-drug and drug treatment of heartburn in pregnancy.

• References total 34 ⇓ :: .
  1. Richter J. E. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 2003, 32, pp. 235-61
  2. Ali R. A., Egan L. J. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol. 2007, 21(5), pp. 793-806
  3. Malfertheiner S. F., Malfertheiner M. V., Kropf S. et al. A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol. 2012 Sep 24, 12, p. 131
  4. Naumann C. R., Zeling C., Napolitano P. G., Ko C. W. Nausea, vomiting, and heartburn in pregnancy: a prospective look at risk, treatment, and outcome. The Journal of Maternal-Fetal and Neonatal Medicine. 2012, Vol. 25 (8), pp. 1488-1493
  5. Aziz Q., Fass R., Gyawali C. P. et al. Functional Esophageal Disorders. Gastroenterology, 2016, 150, pp.1368-1379
  6. Bor S., Kitapcioglu G., Dettmar P., Baxter T. Association of heartburn during pregnancy with the risk of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2007, Sep, 5(9), pp.1035-9
  7. Dowswell T., Neilson J. P. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2008, Issue 4, CD 007065
  8. Attard C. L., Kohli M., Coleman S. et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol. 2002, 186(Suppl 5), pp. S 220-7
  9. Бордин Д. С., Фирсова Л. Д. Альгинатный тест в диагностике эндоскопически негативной формы гастроэзофагеальной рефлюксной болезни. Русский медицинский журнал, 2012, т. 20, № 35., c. 1689-1693
  10. Katz P. O., Castell D. O. Gastroesophageal reflux disease during pregnancy. Gastro Clin N Amer, 1998, 27, pp. 153-167
  11. Vazquez J. C. Constipation, haemorrhoids, and heartburn inpregnancy. Clinical Evidence, 2010, 8, p. 1411
  12. da Silva J. B., Nakamura M. U., Cordeiro J. A. et al. Acupuncture for dyspepsia in pregnancy: a prospective, randomised, controlled study. Acupuncture in Medicine, 2009, 27(2), pp. 50-3
  13. Phupong V., Hanprasertpong T. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2015, Issue 9, CD 011379
  14. Практическая гастроэнтерология. Козлова И. В. руководство для врачей: учебное пособие для системы послевузовского профессионального образования врачей / И. В. Козлова, А. Л. Пахомова. Москва, 2010
  15. Диагностика и лечение болезней органов пищеварения (алгоритмы): учеб. пособие / И. В. Козлова и др. - Изд. 2-е, испр. и доп. - Саратов: Изд-во Сарат. мед. ун-та, 2013
  16. Guideline: Calcium Supplementation in Pregnant Women. Geneva: World Health Organization, 2013.
  17. Hofmeyr G. J., Lawrie T. A., Atallah A. N. et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014, Jun 24(6), CD 001059
  18. Al-Abri S.A., Kearney T. Baking soda misuse as a home remedy: case experience of the California Poison Control System. Journal of Clinical Pharmacy and Therapeutics. 2014, V.39, Issue 1, pp. 73-77
  19. Lindow S. W., Regnéll P., Sykes J., Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (GavisconAdvance) in the treatment of heartburn during pregnancy. Int J Clin Pract. 2003, Apr, 57(3), pp. 175-9
  20. Strugala V., Bassin J., Swales V. S. et al. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet Gynecol. 2012, 2012, 481870
  21. Briggs G. G., Freeman R. Y., Yaffe S. J. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Baltimore, USA: William and Wilkins, 2002
  22. Berkovich M., Elbirt D., Addis A., et al. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. N Engl J Med 2000, 343, pp. 445-6
  23. Choi J. S., Han J. Y., Ahn H. K. et al. Fetal and neonatal outcomes in women taking domperidone during pregnancy. J Obstet Gynaecol. 2013, Feb, 33(2), pp. 160-2
  24. Larson J. D., Patatanian E., Miner P. B., et al. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol, 1997, 90, pp. 83-7
  25. Gill S.K, O’Brien L., Einarson T.R, Gideon K. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009, 104(6), pp.1541-5
  26. Pasternak B., Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010, 363(22), pp. 2114-2123
  27. Matok I1, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci. 2012, Mar, 57(3), pp. 699-705
  28. Nikfar S., Abdollahi M., Moretti M. E. et al. Use of proton pump inhibitors during pregnancy and rates of major malformations; A meta-analysis. Digestive Diseases and Sciences. 2002,47, 7, pp. 1536-1529
  29. Приказ Минздрава России от 01.11.2012 № 572н (ред. от 17.01.2014) «Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)»
  30. Richter J. E. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005, 22(9), pp. 749-757
  31. Mathus-Vliegen L.M., Tytgat G. N. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur. J. Gastroenterol. Hepatol., 1996, 8(7), pp. 635-640
  32. Fraser-Moodie C.A., Norton B., Gornall C. et al. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand. J. Gastroenterol., 1999, 34(4), pp. 337-340
  33. Бурков С. Г. Диагностическая ценность трансабдоминальнои ультрасонографии в выявлении скользящих грыж пищеводного отверстия диафрагмы. “SonoAce-Ultrasound”, 1996, N 1., c. 11-15
  34. Девяткин А. Я., Чугунов А. Н., Гурьев Э. Н. Применение ультразвукового исследования с трехмерной объемной реконструкцией изображения в диагностике грыж пищеводного отверстия диафрагмы. Практическая медицина. Акушерство. Гинекология. Эндокринология. Дерматовенерология, 2012, 09 (65), c. 146-151.

Full text is published :
Kozlova I.V., Pakhomova A.L., Lekareva L.I. DIAGNOSTIC AND THERAPEUTIC APPROACHES TO HEARTBURN IN PREGNANT WOMEN. Experimental and Clinical Gastroenterology Journal. 2017;141(05):43-47
Read & Download full text

1. Ogarev Mordovia State University (Saransk, Russian Federation)

Keywords:liver,pregnancy,autoimmune hepatitis,diagnosis,treatment

Abstract:Presents recent data on autoimmune hepatitis, variants of its clinical symptoms and course. Special attention is paid to the disease during pregnancy and in the postpartum period. Presents current local and international guidelines on the management of pregnant women with autoimmune hepatitis, the possible basic and alternative drug treatment of the disease during pregnancy. The authors present their clinical observations of the author over the course of pregnancy in patients with autoimmune hepatitis.

• References total 61 ⇓ :: .
  1. Рекомендации EASL по лечению аутоиммунного гепатита. J. Hepatol., 2015, vol. 63, pp. 971-1004.
  2. Longhi M. S., Ma Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun., 2009, vol. 17, no. 9, pp.186-189.
  3. Schramm C., Wahl I., Weiler-Normann C. et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J. Hepatol., 2014, vol. 60, pp. 618-624.
  4. Wolf D. C., Raghuraman U. V. Autoimmune Hepatitis. New York Medical College, St John Medical Center. 2011.[Medline].
  5. Czaja A. J. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis., 2009, vol. 29, no. 3, pp. 315-330.
  6. Takahashi H., Zeniya M. Acute presentation of autoimmune hepatitis: Does it exist? A published work review. Hepatol Res., 2011, vol. 41, pp. 498-504.
  7. Zachou K., Muratori P., Koukoulis G. K. et al. Review article: autoimmune hepatitis - Current management and challenges. Aliment Pharmacol Ther., 2013, vol. 38, pp. 887-913.
  8. Czaja A. J., Lindor K. D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology, 2000, vol. 119, pp. 1312-1316.
  9. Czaja A. J. Drug choices in autoimmune hepatitis: part A-Steroids. Expert Rev Gastroenterol Hepatol., 2012, vol. 6, pp. 603-615.
  10. Gronbæk L., Vilstrup H., Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol., 2014, vol. 60, pp. 612-617.
  11. Manns M. P., Lohse A. W., Vergani D. «Autoimmune hepatitis - Update 2015». Journal of Hepatology, 2015, vol. 62, no. 1, S 100-S 111.
  12. Sex Bias in Experimental Immune-Mediated, Drug-Induced Liver Injury in BALB/c Mice: Suggested Roles for Tregs, Estrogen, and IL-6 - PLoS One, doi:10.1371/journal.pone.0061186, April 2013
  13. Obermayer-Straub P., Perheentupa J., Braun S. et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology, 2001, vol. 121, pp. 668-677.
  14. AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis, 2010.
  15. Rigopoulou E. I., Dalekos G., Bogdanos D. P. How common are connective tissue disorders in patients with autoimmune hepatitis? Semin Arthritis Rheum., 2007, vol. 36, p.332.
  16. Teufel A., Weinmann A., Kahaly G. J. et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol., 2010, vol. 44, pp. 208-213.
  17. Ивашкин В. Т., Морозова М. А., Маевская М. В., Буеверов А. О. Современные терапевтические схемы лечения аутоиммунного гепатита. РЖГГК, 2009, № 4, с. 4-12.
  18. Heneghan M. A., Norris S. M., O’Grady J.G. et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut, 2001, vol. 48, pp. 97-102.
  19. Schramm C., Herkel J., Beuers U. et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol., 2006, vol. 101, pp. 556-560.
  20. Werner M., Bjornsson E., Prytz H. et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol., 2007, vol. 42, pp. 986-991.
  21. Westbrook R. H., Yeoman A. D., Kriese S., Heneghan M. A.Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun., 2012, vol. 38, J239-244.
  22. Varma R. R., Michelsohn N. H., Borkowf H. I., Lewis J. D. Pregnancy in cirrhotic and noncirrhotic portal hypertension. Obstetrics and Gynecology, 1977, vol. 50, no. 2, pp. 217-222.
  23. Sandhu B. S., Sanyal A. J. Pregnancy and liver disease. Gastroenterol Clin North Am, 2003, vol. 32, pp. 407-436.
  24. Schreyer P., Caspi E., El-Hindi J.M., Eshchar J. Cirrhosis-pregnancy and delivery: a review. Obstet Gynecol Surv., 1982, vol. 37, pp. 304-312.
  25. Buchel E., Van Steenbergen W., Nevens F., Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol., 2002, vol. 97, pp. 3160-3165.
  26. Samuel D., Riordan S., Strasser S. et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol., 2004, vol. 2, pp. 622-624.
  27. Muratori P., Loffreda S., Muratori L. et al. Spontaneous remission of autoimmune hepatitis during pregnancy. Dig Liver Dis., 2002, vol. 34, pp. 608-609.
  28. Terrabuio D. R., Abrantes-Lemos C.P., Carrilho F. J., Cancado E. L. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol., 2009, vol. 43, pp. 350-356.
  29. Westbrook R. H., Dusheiko G., Williamson A. Болезни печени у беременных. Journal of Hepatology, 2016, vol. 64, pp. 993-945 (Русское издание, Т. 2, № 3)
  30. Adamowicz R., Trzeciak-Supel E., Smolarczyk R. et al. Subsequent pregnancy (twin) in woman with autoimmunological hepatitis. Ginekol Pol., 2005, vol. 76, pp. 742-746.
  31. Еремина Е. Ю. Лекарственный гепатит у беременных. Врач, 2015, № 8, с. 11-13.
  32. Gatselis N. K., Zachou K., Papamichalis P. et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis, 2010, vol. 42, pp. 807-812.
  33. Еремина Е. Ю. Лекарственный гепатит у беременных. Проблемы женского здоровья, 2011, № 4, Т. 6, с. 46-55.
  34. Еремина Е. Ю. Аутоиммунные заболевания печени и беременность. Практическая медицина, 2011, № 6, Т. 54, с. 12-18.
  35. Castiella A., Zapata E., Lucena M. I., Andrade R. J. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol., 2014, vol. 6, pp. 160-168.
  36. Weiler-Normann C., Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol., 2011, vol. 55, pp. 747-749.
  37. Bjornsson E., Talwalkar J., Treeprasertsuk S. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology, 2010, vol. 51, pp. 2040-2048.
  38. Ивашкин В. Т., Буеверов А. О., Маевская М. В., Абдулганиева Д. И. Клинические рекомендации по диагностике и лечению аутоиммунного гепатита. М., 2013.
  39. Ashima M., Kymberly D., Vaidehi R. Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment Hepatitis Research and Treatment. 2011, Article ID 390916, 11 pages doi:10.1155/2011/390916
  40. Candia L., Marquez J., Espinoza L. R. Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma. Semin Arthritis Rheum., 2005, vol. 35, no. 1, pp. 49-56.
  41. Manns M. P., Czaja A. J., Gorham J. D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, vol. 51, pp. 2193-2213.
  42. Czaja A. J., Freese D. K. AASLD practice guidelines. Diagnosis and treatment of autoimmune hepatitis. Hepatology, 2002, vol. 36, no. 2, pp. 479-497.
  43. Murray-Lyon I.M., Stern R. B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet, 1973, vol. 1, pp. 735-737.
  44. Summerskill W. H., Korman M. G., Ammon H. V., Baggenstoss A. H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut, 1975, vol. 16, pp. 876-883.
  45. De Vries F., Bracke M., Leufkens H. G. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum., 2007, vol. 56, pp. 208-214.
  46. Czaja A. J. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Safety, 2008, vol. 7, pp. 319-333.
  47. Chambers C. D., Tutuncu Z. N., Johnson D. et al. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther., 2006, vol. 8, p. 215.
  48. Francella A., Dyan A., Bodian C., et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology, 2003, vol. 124, pp. 9-17.
  49. Casanova M. J., Chaparro M., Domenech E. et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol., 2013, vol. 108, pp. 433-440.
  50. Angelberger S., Reinisch W., Messerschmidt A. et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis, 2011, vol. 5, pp. 95-100.
  51. Manns M. P., Woynarowski M., Kreisel W. et al. European AIH-BUC Study Group: budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterol., 2010, vol. 139, no. 4, pp. 1198-1206.
  52. Woynarowski M., Nemeth A., Baruch Y. et al. European AIH-BUC Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J. Pediatr., 2013, vol. 163, no. 5, pp. 1347-1353.
  53. Hempfling W., Grunhage F., Dilger K. et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology, 2003, vol. 38, no. 1, pp. 196-202.
  54. Mederacke I., Helfritz F., Puls F. et al. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol., 2012, vol. 11, no. 1, pp. 143-144.
  55. Christopher V., Al-Chalabi T., Richardson P. D. et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl., 2006, vol. 12, pp. 1138-1143.
  56. Christopher V., Al-Chalabi T., Richardson P. D. et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl., 2006, vol. 12, pp. 1138-1143.
  57. Еремина Е. Ю., Машарова А. А. Заболевания органов пищеварительной системы у беременных. Саранск, 2009. 200 с.
  58. Еремина Е. Ю. Аутоиммунные заболевания печени и беременность: информация для практического врача. Медицинский альманах, 2011, № 6, Т. 19, c.82-87.
  59. Marten W., Einar B., Hanne P. et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol., 2007, vol. 42, no. 8, pp. 986-991.
  60. Christensen L. A., Dahlerup J. F., Nielsen M. J. et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther., 2008, vol. 28, pp. 1209-1213.
  61. Tripathi D., Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis., 2009, vol. 29. No. 3, pp. 286-96.

Full text is published :
Eremina E.Yu. AUTOIMMUNE HEPATITIS AND PREGNANCY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):48-56
Read & Download full text

1. Veltischev Research ; Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University (Moscow, Russian Federation)

Abstract:Objective: a prospective, open, observational study to assess the tolerability and efficacy of multicomponent probiotics containing Lactobacillus acidophilus, Lactobacillus reuteri, Bifidobacterium lactis and Lactobacillus acidophilus LA-14, Lactobacillus plantarum LP-115, Bifidobacterium longum BB 536 with functional gastrointestinal disorders in early aged children and in frequently ill children. Methods: the first part of the study included 35 infants with functional gastrointestinal disorders during the onset of intestinal colic, dentition, transition from breast to artificial feeding: 25 children received a multicomponent probiotic, 10 children made up a control group. The second part of the study included 40 patients aged 18-24 months during and after taking antibiotics due to virus-bacterial diseases: 20 children received a probiotic and 20 children with similar problems and diseases made up a control group. The study design included 2 visits with an assessment of clinical signs, a coprological study, a quantitative microbiological seeding of feces for the maintenance of microorganisms. The levels of sIgA and lysozyme in coprofiltrates were determined. Results: as a result of assessing the tolerability and clinical effectiveness of the multicomponent probiotic usage in children of the first group with functional gastrointestinal disorders, a good tolerance of the probiotic was established. The improvement of the gastrointestinal tract with its dysfunction associated with dentition, transition from breast to artificial feeding was noted. The probiotic usage in a standard dosage and duration of 2 weeks resulted in clinical (normalization of stool frequency and consistency and other characteristic manifestations: regurgitation, flatulence, frequency and intensity of colic) and laboratory improvement. In the group of children who received the multicomponent probiotic in combination with an antibiotic, an active immunological reaction of the children’s organism to the viral-bacterial disease was noted the increasing concentration of sIgA and lysozyme in coprofiltrates. Conclusion: The multicomponent probiotic containing Lactobacillus acidophilus, Lactobacillus reuteri, Bifidobacterium lactis and Lactobacillus acidophilus LA-14, Lactobacillus plantarum LP-115, Bifidobacterium longum BB 536, can be recommended for widespread usage in early aged children with functional gastrointestinal disorders including disturbance of the stool, flatulence, intestinal colic, as well as in unfavorable conditions, which are associated with a risk of microbiocenosis and immunological intestinal tolerance disorders. Preparations should be used from the first day of antibiotic therapy and continue for 2-3 weeks after the end of admission. The study showed good tolerability of the probiotic, there were no side and undesirable effects.

• References total 11 ⇓ :: .
  1. Кушнарева М. В. Дисбактериоз кишечника у новорожденных и детей первого года жизни. Приложение к журналу Материалы II Российского конгресса «Современные технологии в педиатрии и детской хирургии». - Москва, 2003. - С. 181-185.
  2. Бактериологическая диагностика дисбактериоза кишечника у онкологических больных. (Методические рекомендации)/Состав. А. З. Смолянская, О. П. Марко. - М., 1983. - 26 с.
  3. Лабинская А. С. Микробиология с техникой микробиологических исследований (Справочник). - M.: Медицина, 1978. - С. 164-166.
  4. Барановский А. Ю., Кондрашина Э. А. Дисбактериоз и дисбиоз кишечника. - СПб., 2000. - 209 с.
  5. Хавкин А. И. Микрофлора пищеварительного тракта. - М.: Фонд социальной педиатрии. - 2006. - 414 с.
  6. Дисбиоз кишечника. Руководство по диагностике и лечению./ Под ред. Проф. Ткаченко Е. И., проф. Суворова А. Н. - СПб.: Спецлит, 2007. - 238 с.
  7. Корниенко Е. А. Современный подход к коррекции кишечной микробиоты у детей. Методическое пособие для врачей. - СПб, 2007. - 56 с.
  8. Хавкин А. И. Нарушение микробиоценоза кишечника у детей (Методическое пособие). - М., 2016. - 48 с.
  9. Gut microflora. Digestive physiology and pathology.//Edited by: J-C. Rambaud, J-P. Buts, G. Corthier, B. Flourie. - John Libbey Eurotex, Paris. - 2008, - 247 p.
  10. Хавкин А. И., Пампура А. Н., Комарова О. Н., Чусляева А. А. Роль пробиотиков в комплексной терапии атопического дерматита у детей. Вопросы практической педиатрии, 2014, № 6, т. 9, с. 30.
  11. Хавкин А. И., Комарова О. Н. Опыт применения Lactobacillus rhamnosus в педиатрии. Журнал международной медицины,№ 6(11), 2014, с. 101-106

Full text is published :
Khavkin A.I., Komoarova O.N. THE EFFECTIVENESS OF POLYCOMPONENT PROBIOTICS INCLUDING STRAINS OF LACTOBACILLUS ACIDOPHILUS LA-14, LACTOBACILLUS REUTERI AND BIFIDOBACTERIUM LACTIS IN FUNCTIONAL GASTROINTESTINAL DISORDERS IN EARLY AGED CHILDREN: THE RESULTS OF A PROSPECTIVE, OPEN, OBSERVATIONAL STUDY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):57-64
Read & Download full text

1. State of Israel ministry of health Netanya geriatric center (Netanya, Israel)

Keywords:gastroesophageal reflux disease,lower esophageal sphincter,operation,plication,cardia,scheme

Abstract:Surgical treatment of gastroesophageal reflux disease (GERD) is performed in cases where severe symptoms cannot be controlled by conservative methods. Laparoscopic Nissen Fundoplication (LNF) has become the gold standard surgical procedure for management of GERD, which causes a narrowing of the gastroesophageal junction. Several modifications have been proposed to original technique since the results of LNF are not always as good as expected. Often it is not a complicated operation transformed into the kit of manipulations. The relapses ranging from 0.98 % to 42 %. The aims article to substantiate the new tactics of treatment of the GERD. Theoretical foundations: 1) manometric and radiological studies have shown that the failure of the lower esophageal sphincter (LES) is attributable of the weakness of its intra-abdominal portion (2.1 cm from 3.5 cm); 2in the previous study we have shown that in the patients with GERD the LES is not displaced; 3) it was found that the surgical plication of the external anal sphincter and puborectalis muscle increases its sarcomere length and increases anal canal pressure that can be true also for the LES. Conclusion. The scheme of the surgical plication of the intraabdominal part of the LES is offered. This procedure leads to a mechanical narrowing of the cardia, to the narrowing of the LES ring, as well as increases its wall thickness, which implies the ability to restore of its antireflux function.

• References total 17 ⇓ :: .
  1. Yetişir F1, Salman AE, Durak D, Kiliç M. Laparoscopic fundoplication with double sided posterior gastropexy: a different surgical technique. Int J Surg. 2012;10(9):532-6.
  2. Nissen R (1961) Gastropexy and ‘‘fundoplication’’ in surgical treatment of hiatal hernia. Am J Dig Dis 6:954-961
  3. Antonino A, Giorgio R, Giuseppe F, et al. Hiatal hernia repair with gore bio-a tissue reinforcement: our experience. Case Rep Surg. 2014;2014:851278.
  4. Baerg J1, Thorpe D 1, Gasior A2, Vannix R 1, Tagge E 1, Peter SS 2. Factors Associated with Mortality after Nissen Fundoplication in Children. Eur J Pediatr Surg. 2014 May 2. [Epub ahead of print].
  5. Yamamoto SR, Hoshino M, Nandipati KC, Lee TH, Mittal SK. Long-term outcomes of reintervention for failed fundoplication: redo fundoplication versus Roux-en-Y reconstruction. Surg Endosc. 2014 Jan;28(1):42-8.
  6. Franciosa M, Triadafilopoulos G, Mashimo H. Stretta Radiofrequency Treatment for GERD: A Safe and Effective Modality. Gastroenterol Res Pract. 2013;2013:783815. Epub 2013 Sep 2. Review.
  7. Min, M. Characteristics of achalasia subtypes in untreated Chinese patients: a high-resolution manometry study / Min M., Peng L. H., Yang Y. S. et al. // J. Dig. Dis. - 2012. - Vol. 13, No. 10. - P. 504-509. doi: 10,1111/j.1751-2980,2012,00622, x. 4.
  8. Ackermann, C. Esophageal manometry prior to andfollowing anti-reflux surgery / Ackermann C., Rothenbrhler J. M., Martinoli S., Muller C. // Schweiz. Med. Wochenschr. - 1991. - Vol. 121, No. 21. - P. 797-800. 5.
  9. Marshall, R. E. Esophageal body length, lower esophageal sphincter length, position and pressure in health and disease / Marshall R. E., Anggiansah A., Anggiansah C. L. et al. // Dis. Esophagus. - 1999. - Vol. 12, No. 4. - P. 297-302.
  10. Gomez, R. Esophageal pH monitoring of postprandial gastroesophageal reflux. Comparison between healthy subjects, patients with gastroesophageal reflux and patients treated with Nissen fundoplication / Gomez R., Moreno E., Seoane J. et al. // Dig. Dis. - 1993. - Vol. 11, No. 6. - P. 354-362.
  11. Левин МД, Троян ВВ. Нормальная анатомия и физиология пищевода в рентгенологическом изображении и его роль в диагностике гастроэзофагеальной рефлюксной болезни. Медицина (Беларусь). 2006, № 3, с. 32-36.
  12. Левин МД, Коршун З, Мендельсон Г. Патологическая физиология гастроэзофагеальной рефлюксной болезни. Гипотеза. Эксп Клин Гастроэнтерол. 2013(5):72-88.
  13. Chandrasoma P1, Wijetunge S, Ma Y, Demeester S, Hagen J, Demeester T. The dilated distal esophagus: a new entity that is the pathologic basis of early gastroesophageal reflux disease. Am J Surg Pathol. 2011 Dec;35(12):1873-81.
  14. Lee YY 1, Whiting JG, Robertson EV, Derakhshan MH, Smith D, McColl KE. Measuring movement and location of the gastroesophageal junction: research and clinical implications. Scand J Gastroenterol. 2013 Apr;48(4):401-11.
  15. Rubesin SE 1, Furth EE, Rose D, Levine MS, Laufer I. The effects of distention of the colon during air-contrast barium enema on colonic morphology: anatomic correlation. AJR Am J Roentgenol. 1995 Jun;164(6):1387-9.
  16. Crookes PF1. Physiology of reflux disease: role of the lower esophageal sphincter. Surg Endosc. 2006 Apr;20 Suppl 2: S 462-6. Epub 2006 Mar 23.
  17. Mittal RK1, Sheean G2, Padda BS 1, Rajasekaran MR 1. Length tension function of puborectalis muscle: implications for the treatment of fecal incontinence and pelvic floor disorders. J Neurogastroenterol Motil. 2014 Oct 30;20(4):539-46. doi: 10.5056/jnm14033.

Full text is published :
Levin M.D. THE THEORETICAL JUSTIFICATION OF A NEW SURGICAL TECHNIQUE IN GASTROESOPHAGEAL REFLUX DISEASE. RESTORATION FUNCTION OF THE LOWER ESOPHAGEAL SPHINCTER (CARDIOPLICATION). Experimental and Clinical Gastroenterology Journal. 2017;141(05):65-69
Read & Download full text

1. Kazan State Medical University (Kazan, Russian Federation)
2. Republican Clinical Hospital (Kazan, Russian Federation)

Keywords:Turner’s syndrome,mosaic,pregnancy,cirrhosis,autoimmune hepatitis

Abstract:The clinical case of pregnancy in patient with mosaic Turner’s Syndrome and cirrhosis in the outcome of Autoimmune Hepatitis is presented in the article.

• References total 8 ⇓ :: .
  1. Doğer E. Reproductive and obstetric outcomes in mosaic Turner’s Syndrome: a cross-sectional study and review of the literature / E. Doğer, Y. Çakıroğlu, Y. Ceylan et al. // Reproductive Biology and Endocrinology. - 2015. - № 13. - Р. 59-66.
  2. Колотий А. Д. Цитогенетические и молекулярно-цитогенетические (FISH И MCB) исследования синдрома Шерешевского-Тернера: ретроспективный анализ 96 случаев / А. Д. Колотий, Ворсанова С. Г., Юров Ю. Б. и др. // Современные проблемы науки и образования. - 2016. - № 5. - С. 16-29.
  3. Вяткина С. В. Современные представления о синдроме Шерешевского-Тернера / С. В. Вяткина, Т. В. Кузнецова // Журнал акушерства и женских болезней. - 2007. - № 1. - С. 56-63.
  4. Jørgensen K. T. Autoimmune diseases in women with Turner’s syndrome / K. T. Jørgensen, K. Rostgaard, I. Bache et al. // Arthritis & Rheumatology. - 2010. - № 62(3). - Р. 658-666.
  5. Mortensen K. H. Increased prevalence of autoimmunity in Turner syndrome - influence of age / K. H. Mortensen, L. Cleemann, B. E. Hjerrild et al. // Clin Exp Immunol. - 2009. - № 156(2). - Р. 205-210.
  6. Montano-Loza A. J. Targeting Hepatic Fibrosis in Autoimmune Hepatitis / A. J. Montano-Loza, R. B. Thandassery, A. J. Czaja // Digestive Diseases and Sciences. - 2016. - № 61(11). - Р. 3118-3139.
  7. Koulouri O. Liver dysfunction in Turner’s syndrome: prevalence, natural history and effect of exogenous oestrogen / O. Koulouri, J. Ostberg, G. S. Conway // Clin Endocrinol (Oxf). - 2008. - № 69(2). - Р. 306-310.
  8. Tarani L. Pregnancy in patients with Turner’s syndrome: six new cases and review of literature / L. Tarani, S. Lampariello, G. Raguso et al. // Gynecol Endocrinol. - 1998. - № 12(2). - Р. 83-87.

Full text is published :
Abdulganieva D.I., Odintsova A.Kh., Mukhametova D.D., Ramazanova A.Kh. et al. PREGNANCY IN PATIENT WITH MOSAIC TURNER’S SYNDROME AND CIRRHOSIS IN THE OUTCOME OF AUTOIMMUNE HEPATITIS TYPE 1. Experimental and Clinical Gastroenterology Journal. 2017;141(05):70-73
Read & Download full text

1. V. I. Vernadsky Crimean Federal University (Simferopol, Russian Federation)

Abstract:The article is devoted to the history of discovery and study of one of the most important organs of the digestive and endocrine system of the body - the pancreas. Chronologically, key discoveries in pancreatic anatomy, histology, physiology and biochemistry are presented. Brief data about life and activity of scientists, whose names immortalized in pancreatic eponyms (J. G. Wirsung, G. D. Santorini, P. Langerhans) are given. Circumstances of their discoveries are described.

• References total 8 ⇓ :: .
  1. Howard J. M., Hess W. History of the pancreas. Mysteries of a hidden organ. New York: Springer, 2002. - 729 p.
  2. Кутя С. А. Жизнь и смерть Иоганна Георга Вирсунга (к 370-летию со дня открытия протока поджелудочной железы) // Клінічна анатомія та оперативна хірургія. - 2012. - № 3. - 119-121.
  3. Кутя С. А. Вклад студентов в становление морфологии. Из истории открытий // Труды КГМУ им. С. И. Георгиевского «Проблемы, достижения и перспективы развития медико-биологических наук и практического здравоохранения». - 2010. - Т. 146, ч. V. - С. 20-23.
  4. Bassi C., Malleo G. The unsolved mystery of Johann Georg Wirsung and of (his?) pancreatic duct // Surgery. - 2011. - № 1. - Р. 153-155.
  5. Flati G., Andren-Sandberg A. Wirsung and Santorini: the men behind ducts // Pancreatology. - 2002. - № 2. - Р. 4-11.
  6. Губергриц Н. П. Панкреатология: от прошлого к будущему // Новости медицины и фармации. - 2007, № 226. - Режим доступа: www.novosti.mif-ua.com/archive/issue-3888/article-3906/
  7. Ragland E. R. Experimenting with chymical bodies: Reinier de Graaf’s investigations of the pancreas // Early science and medicine. - 2008. - № 6. - Р. 615-664.
  8. Kleinerman R., John A., Etienne D. et al. Giovanni Domenico Santorini (1681-1737): a prominent physician and meticulous anatomist // Clin. Anat. - 2014. - № 4. - Р. 545-547.
  9. Modlin I. M., Kidd M. The Paradox of the Pancreas: from Wirsung to Whipple. - Hannover: Politzki Print Productions, 2004. - 430 p.
  10. Breathnach C. S. Claude Bernard and his revelations in physiology // Ir. J. Med. Sci. - 2014. - № 1. - Р. 139-146.
  11. Губергриц Н. Б. Расширение терапевтических возможностей ферментных препаратов: прогресс от таблеток до минимикросфер Креона // Русский медицинский журнал - 2004. - № 24. - С. 1395-1401.
  12. Железнякова А. В. Поль Лангерганс. 140 лет открытию островков поджелудочной железы // Сахарный диабет. - 2009. - № 2. - С. 94-95.
  13. Быков В. Л. Пауль Лангерганс - короткая жизнь и бессмертные открытия (к 125-летию со дня смерти) // Морфология. - 2013. - № 6. - С. 85-91.
  14. Кутя С. А., Пикалюк В. С. О деятельности врачей-труэнтов, вошедших в историю морфологии в виде эпонимов // Морфологія. - 2010. - № 1. - С. 74-78.
  15. Cresticelli F. Friedrich Wilhelm Kuhne (1837-1900) // Vision Res. - 1977. - Vol. 17. - P. 1317-1323.
  16. Fossati P. Edouard Laguesse at Lille in 1893 created the term “endocrine” and opened the endocrinology era // Hist. Sci. Med. - 2004. - Vol. 38, № 4. - Of P. 433-439.
  17. Копаладзе Р. А. От Л. В. Соболева до Нобелевской премии Бантинга. К 140-летию со дня рождения Леонида Васильевича Соболева (1876-1919) // Бюллетень Национального научно-исследовательского института общественного здоровья имени Н. А. Семашко. - 2016. - № 2. - С. 211-212.
  18. Сорокина Л. А. Леонид Васильевич Соболев (1876-1919): у истоков открытия инсулина // Сахарный диабет. - 2013. - № 1. - С. 103-105.
  19. Дьяченко А. П. Словарь авторских терминов, понятий и названий в медицине / А. П. Дьяченко. - М.: Триада-Х, 2002. - 368 с.
  20. Резников А. Г. Фредерик Бантинг и открытие инсулина (к 75-летию со дня трагической гибели) // Международный эндокринологический журнал. - 2016. - № 5. - С. 99-102.
  21. Blackman B. The use of glucagon in insulin coma therapy // Psychiatric Quarterly. - 1961. - № 3. - P. 482-487.
  22. Harper A. A., Raper H. S. Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of small intestine // Journal of Physiology. - 1943. - Vol. 102. - P. 115-125.
  23. Jorpes J. E., Mutt V., Toczko K. Further purification of cholecystokinin and pancreozymin // Acta Chemica Scandinavica. - 1964. - Vol. 18. - P. 2408-2410.
  24. Walker J. Frederick Sanger (1918-2013) // Nature. - 2014. - Vol. 505. - Р. 27.
  25. Tartakoff A. M. George Emil Palade: charismatic virtuoso of cell biology // Nat. Rev. Mol. Cell Biol. - 2002. - № 3. - P. 871-876.
  26. Коротько Г. Ф. Секреция поджелудочной железы. - М.: Триада-Х, 2002. - 224 с.

Full text is published :
Kutia S.A., Sataieva T.P., Kriventsov M.A., Polishchuk E.A. PANCREAS: HISTORY IN A TIMELINE. Experimental and Clinical Gastroenterology Journal. 2017;141(05):74-78
Read & Download full text

1. State funded institution of higher professional education “Moscow State Medical and Dental University of A. I. Evdokimov” (Moscow, Russian Federation)

Abstract: Yury Borisovich Belousov is rightly called the founder of clinical pharmacology in the Russian Federation. Yu. B. Belousov was the Chief Clinical Pharmacologist and Deputy Chairman of the Pharmacological Committee of the Ministry of Health of the Russian Federation, Chairman of the Interdepartmental Council on Antibiotic Policy at the Ministry of Health of the Russian Federation, Deputy Chairman of the Scientific Organizing Committee and Chairman of the Council of Experts of the “Federal Manual for Doctors on Drug Use”. Yuri Borisovich was one of the founders and vice-president of the Russian National Congress "Man and Medicine". Thanks to him, congresses and congresses of the Russian Scientific Medical Society of Therapists acquired a new sound. The article is in Russian.

Full text is published :
Lazebnik L.B. OF THE MEMORY OF YURI BORYSOVICH BELOUSOV. Experimental and Clinical Gastroenterology Journal.2017;141(05):79-79
Read & Download full text